已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Advancing treatment efficacy: combined therapy of eribulin, anlotinib, and camrelizumab in advanced or metastatic retroperitoneal liposarcoma

医学 艾瑞布林 不良事件通用术语标准 无进展生存期 内科学 实体瘤疗效评价标准 肿瘤科 养生 脂肪肉瘤 外科 不利影响 化疗 进行性疾病 肉瘤 癌症 转移性乳腺癌 病理 乳腺癌
作者
Weiwei Jia,Jianhui Wu,Hongtao Zhang,Yan Wu,Daoning Liu,Zhen Wang,Xiaopeng Wang,Cheng‐Peng Li,Chunyi Hao
出处
期刊:Therapeutic Advances in Medical Oncology [SAGE]
卷期号:16
标识
DOI:10.1177/17588359241276968
摘要

Background: Retroperitoneal liposarcoma (RLPS) typically shows limited response to standard chemotherapy, presenting a challenge in treating advanced or metastatic RLPS. Objective: This study aimed to evaluate the potential advantages of a combined therapeutic strategy utilizing eribulin, anlotinib, and camrelizumab. Design: Between December 2020 and March 2023, this retrospective study enrolled patients with advanced or metastatic RLPS who received treatment at Peking University Cancer Hospital Sarcoma Center. The treatment regimen involved eribulin plus anlotinib and camrelizumab administered every 3 weeks (Q3W). Methods: Efficacy was assessed following the Response Evaluation Criteria in Solid Tumors version 1.1, while safety was evaluated using the Common Terminology Criteria for Adverse Events version 5.0. Results: The study included 47 patients with RLPS with a median age of 55.5 years. Patients received a median of 4.5 (range, 2–21) cycles of treatment. Notably, partial response was observed in 8 patients (18.2%), while 25 (56.8%) exhibited stable disease. The objective response rate (ORR) and disease control rate were 18.2% and 75%, respectively. Significant differences in ORR were observed among histological subtypes (well-differentiated vs de-differentiated vs myxoid: 0 vs 17.9% vs 50%; p = 0.039). Six patients underwent surgery before disease progression, and one patient with myxoid liposarcoma (MLPS) had a pathological complete response. With a median follow-up of 21.8 (range, 2.7–30.7) months, the median progression-free survival (mPFS) was 6.9 (95% confidence interval (CI), 4.7–9.1) months, and the 6-month PFS rate was 60.5%. Based on various histological subtypes, the mPFS was 8.4 (95% CI, 4.1–12.7) months with well-differentiated liposarcoma, 5.8 (95% CI, 3.3–8.3) months with de-differentiated liposarcoma and not reached with MLPS, respectively. Treatment-related adverse events (TRAEs) of any grade occurred in 36 (76.6%) patients, with grade 3 or higher TRAEs in 21 (44.7%) patients. The most common TRAEs were neutropenia (53.2%), proteinuria (21.3%), and anorexia (21.3%). Conclusion: The combined treatment strategy involving eribulin, anlotinib, and camrelizumab showed promising efficacy and manageable safety in patients with advanced or metastatic RLPS, particularly in those with MLPS.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
顺顺欣完成签到 ,获得积分10
2秒前
4秒前
5秒前
8秒前
10秒前
10秒前
好运来完成签到,获得积分10
12秒前
bkagyin应助迷人的Jack采纳,获得10
16秒前
yi发布了新的文献求助10
16秒前
沐晴完成签到,获得积分10
16秒前
orixero应助哈哈哈采纳,获得10
18秒前
yzw完成签到,获得积分10
19秒前
搬工的砖人完成签到,获得积分10
20秒前
听话的蜡烛完成签到,获得积分10
21秒前
黑白菜发布了新的文献求助10
22秒前
只要平凡完成签到 ,获得积分10
22秒前
星辰大海应助风中的语蝶采纳,获得10
22秒前
hope完成签到,获得积分10
26秒前
shashali发布了新的文献求助10
28秒前
科研通AI2S应助核桃采纳,获得10
29秒前
30秒前
hope发布了新的文献求助10
30秒前
31秒前
111完成签到 ,获得积分10
35秒前
36秒前
奕柯完成签到,获得积分10
39秒前
大个应助wawaa采纳,获得10
41秒前
41秒前
Liver发布了新的文献求助10
42秒前
情怀应助嘎嘎咻采纳,获得10
45秒前
49秒前
51秒前
Lucas应助科研通管家采纳,获得10
51秒前
小蘑菇应助奋斗的杰采纳,获得10
51秒前
51秒前
打打应助科研通管家采纳,获得10
51秒前
斯文败类应助科研通管家采纳,获得10
51秒前
天天快乐应助科研通管家采纳,获得20
51秒前
汉堡包应助科研通管家采纳,获得10
51秒前
大个应助风中的语蝶采纳,获得10
51秒前
高分求助中
Evolution 10000
ISSN 2159-8274 EISSN 2159-8290 1000
Becoming: An Introduction to Jung's Concept of Individuation 600
Ore genesis in the Zambian Copperbelt with particular reference to the northern sector of the Chambishi basin 500
A new species of Coccus (Homoptera: Coccoidea) from Malawi 500
A new species of Velataspis (Hemiptera Coccoidea Diaspididae) from tea in Assam 500
PraxisRatgeber: Mantiden: Faszinierende Lauerjäger 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3161877
求助须知:如何正确求助?哪些是违规求助? 2813104
关于积分的说明 7898643
捐赠科研通 2472140
什么是DOI,文献DOI怎么找? 1316350
科研通“疑难数据库(出版商)”最低求助积分说明 631278
版权声明 602129